Clinical Data Early data for heart drug affirm Lilly’s billion-dollar bet on Verve BioPharma DiveThe base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) BioPharma Dive The base editing medicine lowered bad cholesterol levels along with a key protein, clearing the way for a Phase 2 study. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly to buy trio of vaccine developers in $3.8bn outlayNext: FDA delays verdict on AZ breast cancer drug Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
